Spero Therapeutics (NASDAQ:SPRO) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a buy rating to a hold rating in a research note published on Saturday morning.

SPRO has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Wednesday, October 8th. Zacks Research lowered Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 13th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.00.

Spero Therapeutics Stock Performance

Shares of NASDAQ:SPRO opened at $2.43 on Friday. The business has a fifty day moving average of $2.36 and a 200-day moving average of $2.30. Spero Therapeutics has a twelve month low of $0.51 and a twelve month high of $3.22. The firm has a market cap of $136.90 million, a PE ratio of -3.08 and a beta of 1.46.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.12. The business had revenue of $5.44 million for the quarter, compared to the consensus estimate of $12.00 million. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. On average, analysts anticipate that Spero Therapeutics will post -1.2 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Esther Rajavelu sold 40,270 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the transaction, the insider owned 869,450 shares of the company’s stock, valued at $2,060,596.50. This represents a 4.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

Institutional investors have recently made changes to their positions in the stock. Invesco Ltd. acquired a new position in Spero Therapeutics in the second quarter valued at about $43,000. Dimensional Fund Advisors LP bought a new stake in shares of Spero Therapeutics in the 3rd quarter valued at about $55,000. Quadrature Capital Ltd bought a new stake in shares of Spero Therapeutics in the 2nd quarter valued at about $90,000. Axxcess Wealth Management LLC acquired a new stake in shares of Spero Therapeutics in the 2nd quarter valued at approximately $94,000. Finally, Capital Asset Advisory Services LLC bought a new position in Spero Therapeutics during the 2nd quarter worth approximately $94,000. 25.60% of the stock is owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.